-
Je něco špatně v tomto záznamu ?
The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study
P. Neven, C. Markopoulos, M. Tanner, M. Marty, R. Kreienberg, L. Atkins, A. Franquet, M. Gnant, S. Neciosup, P. Tesarova, S. Barni, V. Deschamp,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
- MeSH
- adherence k farmakoterapii statistika a číselné údaje MeSH
- adjuvantní chemoterapie MeSH
- hormonální protinádorové látky terapeutické užití MeSH
- inhibitory aromatasy terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfadenektomie MeSH
- mastektomie MeSH
- nádory prsu farmakoterapie MeSH
- nitrily terapeutické užití MeSH
- postmenopauza MeSH
- senioři MeSH
- triazoly terapeutické užití MeSH
- vzdělávání pacientů jako téma metody MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
The CARIATIDE study was designed to assess the impact of educational materials (EMs) on compliance and persistence rates with aromatase inhibitor (AI) treatment in postmenopausal women with hormone-receptor-positive early breast cancer. Patients were randomized to standard AI treatment (Group A; N = 1379) or standard AI treatment plus EMs containing information on a range of breast-cancer-related topics (Group B; N = 1379). Standardized questionnaires assessed investigator-perceived levels of care and evaluated patient compliance and behavior. At 1 year, there was no significant difference in compliance between Group A and Group B (81% vs. 82%, p = 0.4524). However, higher compliance in patients receiving EMs was observed in Sweden/Finland (p = 0.0246). Compliance with initial AI and persistence rate were not significantly altered by EM. Other factors associated with improved compliance, irrespective of EMs, e.g. administration of chemotherapy were identified.
Breast Unit Athens University Medical School and Department of Surgery Athens Greece
Department of Oncology 1st Faculty of Medicine and General Teaching Hospital Prague Czech Republic
Department of Oncology Tampere University Hospital Tampere Finland
Department of Surgery and Comprehensive Cancer Centre Medical University of Vienna Vienna Austria
Instituto Nacional de Enfermedades Neoplasicas Lima Peru
International Drug Development Institute Ottignies Louvain la Neuve Belgium
Multidisciplinary Breast Centre and Gynaecological Oncology UZ Leuven Leuven Belgium
Oncologia Medica Azienda Ospedaliera Treviglio Caravaggio Treviglio Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15014446
- 003
- CZ-PrNML
- 005
- 20150430085842.0
- 007
- ta
- 008
- 150420s2014 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.breast.2014.02.009 $2 doi
- 035 __
- $a (PubMed)24675394
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Neven, Patrick $u Multidisciplinary Breast Centre and Gynaecological Oncology, UZ Leuven, Leuven, Belgium. Electronic address: patrick.neven@uzleuven.be.
- 245 14
- $a The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study / $c P. Neven, C. Markopoulos, M. Tanner, M. Marty, R. Kreienberg, L. Atkins, A. Franquet, M. Gnant, S. Neciosup, P. Tesarova, S. Barni, V. Deschamp,
- 520 9_
- $a The CARIATIDE study was designed to assess the impact of educational materials (EMs) on compliance and persistence rates with aromatase inhibitor (AI) treatment in postmenopausal women with hormone-receptor-positive early breast cancer. Patients were randomized to standard AI treatment (Group A; N = 1379) or standard AI treatment plus EMs containing information on a range of breast-cancer-related topics (Group B; N = 1379). Standardized questionnaires assessed investigator-perceived levels of care and evaluated patient compliance and behavior. At 1 year, there was no significant difference in compliance between Group A and Group B (81% vs. 82%, p = 0.4524). However, higher compliance in patients receiving EMs was observed in Sweden/Finland (p = 0.0246). Compliance with initial AI and persistence rate were not significantly altered by EM. Other factors associated with improved compliance, irrespective of EMs, e.g. administration of chemotherapy were identified.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a hormonální protinádorové látky $x terapeutické užití $7 D018931
- 650 _2
- $a inhibitory aromatasy $x terapeutické užití $7 D047072
- 650 _2
- $a nádory prsu $x farmakoterapie $7 D001943
- 650 _2
- $a adjuvantní chemoterapie $7 D017024
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lymfadenektomie $7 D008197
- 650 _2
- $a mastektomie $7 D008408
- 650 _2
- $a adherence k farmakoterapii $x statistika a číselné údaje $7 D055118
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nitrily $x terapeutické užití $7 D009570
- 650 _2
- $a vzdělávání pacientů jako téma $x metody $7 D010353
- 650 _2
- $a postmenopauza $7 D017698
- 650 _2
- $a triazoly $x terapeutické užití $7 D014230
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Markopoulos, Christos $u Breast Unit, Athens University Medical School and Department of Surgery, Athens, Greece.
- 700 1_
- $a Tanner, Minna $u Department of Oncology, Tampere University Hospital, Tampere, Finland.
- 700 1_
- $a Marty, Michel $u Hôpital St Louis, Paris, France.
- 700 1_
- $a Kreienberg, Rolf $u Universitäts-Frauenklinik Ulm, Ulm, Germany.
- 700 1_
- $a Atkins, Louise $u University College London, London, UK. $7 gn_A_00009778
- 700 1_
- $a Franquet, Ann $u International Drug Development Institute, Ottignies-Louvain-la-Neuve, Belgium.
- 700 1_
- $a Gnant, Michael $u Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Neciosup, Silvia $u Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
- 700 1_
- $a Tesarova, Petra $u Department of Oncology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic.
- 700 1_
- $a Barni, Sandro $u Oncologia Medica, Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, Italy.
- 700 1_
- $a Deschamp, Veronique $u AstraZeneca, Brussels, Belgium.
- 773 0_
- $w MED00000846 $t Breast (Edinburgh, Scotland) $x 1532-3080 $g Roč. 23, č. 4 (2014), s. 393-9
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24675394 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150420 $b ABA008
- 991 __
- $a 20150430090146 $b ABA008
- 999 __
- $a ok $b bmc $g 1072027 $s 897324
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 23 $c 4 $d 393-9 $i 1532-3080 $m Breast $n Breast $x MED00000846
- LZP __
- $a Pubmed-20150420